Cargando…

Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells

Escape from cellular senescence induction is a potent mechanism for chemoresistance. Cellular senescence can be induced in breast cancer cell lines by the removal of estrogen signaling with tamoxifen or by the accumulation of DNA damage induced by the chemotherapeutic drug doxorubicin. Long term cul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Jackson R., Lehmann, Brian D., Chappell, William H., Abrams, Stephen L., Steelman, Linda S., McCubrey, McCubrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2011
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248208/ https://www.ncbi.nlm.nih.gov/pubmed/21881167

Ejemplares similares

Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
por: Chappell, William H., et al.
Publicado: (2020)

Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity
por: Chappell, William H., et al.
Publicado: (2012)

Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity
por: Steelman, Linda S., et al.
Publicado: (2011)

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
por: Sokolosky, Melissa L., et al.
Publicado: (2011)

Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression
por: Steelman, Linda S., et al.
Publicado: (2017)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

Recent progress in targeting cancer
por: Demidenko, Zoya N., et al.
Publicado: (2011)

Recent discoveries in the cycling, growing and aging of the p53 field
por: McCubrey, James A., et al.
Publicado: (2012)

Where are we with understanding of COVID-19?
por: Akula, Shaw M., et al.
Publicado: (2020)

Where are we with understanding of COVID-19?
por: Akula, Shaw M., et al.
Publicado: (2020)

The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
por: Simioni, Carolina, et al.
Publicado: (2013)

TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer
por: Akula, Shaw M., et al.
Publicado: (2020)

The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
por: Martelli, Alberto M., et al.
Publicado: (2010)

Cell-to-cell lactate shuttle operates in heart and is important in age-related heart failure
por: Gizak, Agnieszka, et al.
Publicado: (2020)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

Foreword for the special issue advances in COVID-19: Biology and clinic
por: McCubrey, James A., et al.
Publicado: (2020)

APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
por: McCubrey, James Andrew, et al.
Publicado: (2022)

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties
por: McCubrey, James A., et al.
Publicado: (2022)

The Reverse Warburg Effect Is Associated with Fbp2-Dependent Hif1α Regulation in Cancer Cells Stimulated by Fibroblasts
por: Duda, Przemysław, et al.
Publicado: (2020)

Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes
por: Berman, Albert E., et al.
Publicado: (2012)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Neuron-derived transthyretin modulates astrocytic glycolysis in hormone-independent manner
por: Zawiślak, Alina, et al.
Publicado: (2017)

Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2013)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells
por: Cusimano, Antonella, et al.
Publicado: (2014)

Analysis of the B-RAF(V600E) mutation in cutaneous melanoma patients with occupational sun exposure
por: CANDIDO, SAVERIO, et al.
Publicado: (2014)

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2016)

The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19
por: Basile, Maria Sofia, et al.
Publicado: (2022)

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
por: McCubrey, James A., et al.
Publicado: (2022)

Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer
por: Pappalardo, Francesco, et al.
Publicado: (2016)

Dimeric and tetrameric forms of muscle fructose-1,6-bisphosphatase play different roles in the cell
por: Wiśniewski, Janusz, et al.
Publicado: (2017)

Lamin B1 Accumulation’s Effects on Autosomal Dominant Leukodystrophy (ADLD): Induction of Reactivity in the Astrocytes
por: Ratti, Stefano, et al.
Publicado: (2021)

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014)

The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias
por: Martelli, Alberto M., et al.
Publicado: (2020)

Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
por: Martelli, Alberto M., et al.
Publicado: (2022)

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
por: Cani, Alice, et al.
Publicado: (2015)

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
por: Cervello, Melchiorre, et al.
Publicado: (2012)

GSK3 as a Regulator of Cytoskeleton Architecture: Consequences for Health and Disease
por: Hajka, Daria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rmd3qudtdk0uhi9dftfj0hi6td